Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.
Hewamadduma C. et al, (2025), J Neurol, 272
The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD.
Samadzadeh S. et al, (2025), J Neurol, 272
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
Nowak RJ. et al, (2025), N Engl J Med
Sleep-related hypermotor epilepsy in a patient with myelin-oligodendrocyte-glycoprotein antibody disease
Holm-Mercer L. et al, (2025), BMJ Case Reports, 18, e263755 - e263755
Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD.
Chan F. et al, (2025), Mult Scler
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data.
Slioui A. et al, (2025), Orphanet J Rare Dis, 20
The role of N-glycans in regulatory T cells in autoimmunity.
Carneiro P. et al, (2025), Autoimmun Rev, 24
Clinical data and reporting quality in NMDAR-antibody encephalitis and pregnancy: a systematic review
Harris SL. et al, (2025), BMJ Neurology Open, 7, e001005 - e001005
Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
Chen B. et al, (2025), Neurology, 104
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience.
Moniz Dionísio J. et al, (2025), J Neurol Neurosurg Psychiatry
Daily self-injection of zilucoplan improved symptoms in people with generalized myasthenia gravis in the RAISE clinical study: a Plain Language Summary of Publication
Howard JF. et al, (2025), Future Neurology, 20
Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) Associated with GlyR Antibody in an APECED Patient.
Ochoa S. et al, (2024), J Clin Immunol, 45
The influence of MOGAD on diagnosis of multiple sclerosis using MRI
Geraldes R. et al, (2024), Nature Reviews Neurology
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders.
Oertel FC. et al, (2024), Neurol Neuroimmunol Neuroinflamm, 11